04/09/14: See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Back to Top

Contributors:

                          
Amy Comstock Rick, CEO, Parkinson’s Action Network
Sally Greenberg, Executive Director, National Consumers League
Sharon F. Terry , President and CEO , Genetic Alliance
Wendy K.D. Selig , President and CEO, Melanoma Research Alliance
Millicent Gorham, #PhRMA14 Attendee, Nat. Black Nurses Assoc.
Andrew Sperling, #PhRMA14 Attendee, NAMI
Carl Schmid, Deputy Executive Director, The AIDS Institute
Scott Smith, #PhRMA14 Attendee, GlaxoSmithKline
Christopher W. Hansen, President, ACS CAN
Randall L. Rutta, Chief Strategy Officer, Executive Vice President, Easter Seals
Danielle Pere, #PhRMA14 Attendee, ACPM
David Miller, President and CEO , iBIO
Jeffrey M. Gallagher, CEO, Virginia Bio

Join The Conversation

03/26/14: What is the greatest issue facing Parkinson’s patients today, and what can be done to accelerate the research and development of new therapies to help them?

Back to Top

Contributors:

                  
Amy Comstock Rick, CEO, Parkinson’s Action Network
Todd Sherer, CEO, Michael J. Fox Foundation
Gabriela Lavezzari, AVP, Scientific Affairs , PhRMA
Tom Isaacs, Co-Founder, Cure Parkinson's Trust
Terri Reinhart, Parkinsons Patient, Artist & Writer
EPDA, Contributor, Non-Profit
NINDS, Initiative, NIH
Peter Schmidt, CIO, VP, NPF
Robin Elliott, President, Parkinson’s Disease Foundation

Join The Conversation

03/19/14: What steps can we take to increase patient participation in clinical trials, particularly among diverse populations?

Back to Top

Contributors:

          
Ho Luong Tran, President & CEO, NCAPIP
Gary Puckrein, President & CEO, Minority Quality Forum
Dr. Bill Chin, Scientific & Regulatory Affairs, PhRMA
Amy Hinojosa, Executive Director, MANA
Lisa Treviño, VP, Research & Development, DHR

Join The Conversation

03/17/14: What would the recent proposed changes to Medicare Part D’s six protected classes mean for patients?

Back to Top

Contributors:

        
Carl Schmid, Deputy Executive Director, The AIDS Institute
Angela Ostrom, VP, Public Policy & Advocacy, Epilepsy Foundation
Allen Doederlein, President, DBSA
Mary R. Grealy, President , HLC

Join The Conversation

03/05/14: What are expectations that can come from the Accelerating Medicines Partnership?

Back to Top

Contributors:

          
Virginia T. Ladd, President , AARDA
Lon Cardon, SVP, Alternative Discovery & Development, GlaxoSmithKline
Dr. Gary J. Nabel, Chief Scientific Officer, Sanofi
James P. Sullivan, Ph.D., VP, Pharmaceuticals Discovery, AbbVie
Leslie Hanrahan, VP, Education & Research, Lupus Foundation

Join The Conversation

02/14/14: What are our greatest challenges as we address managing chronic diseases like diabetes?

Back to Top

Contributors:

      
Dr. Bill Chin, Scientific & Regulatory Affairs, PhRMA
Fran Cogen, MD, CDE, Director, Children’s National
Richard A. Insel, M.D., Chief Scientific Officer, JDRF

Join The Conversation

01/22/14: STEM education, skills and training are critical to U.S. economic growth and competitiveness. How do we work together to close the current STEM skills gap and best position the U.S. to retain its leadership in innovation?

Back to Top

Contributors:

            
Carmela Mascio, Senior Research Associate, Cubist
Claudio Alfaro, VP of External Engagement, Citizen Schools
Kathleen Pasley , Director of Development, ASTC
Mae Jemison, Founder, The Jemison Group
Mary Linda Andrews, Director, GSK
Rebecca Lewis, Project Director, EDC

Join The Conversation

Pages